Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · November 29, 2017

Relationship of C-Reactive Protein Reduction to Cardiovascular Event Reduction Following Treatment With Canakinumab

The Lancet

 

Additional Info

The Lancet
Relationship of C-Reactive Protein Reduction to Cardiovascular Event Reduction Following Treatment With Canakinumab: A Secondary Analysis From the CANTOS Randomised Controlled Trial
Lancet 2017 Nov 13;[EPub Ahead of Print], PM Ridker, JG MacFadyen, BM Everett, P Libby, T Thuren, RJ Glynn,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading